GlobeNewswire
Legionella Testing Market to Reach $421.9 Million by 2027
Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 7. – Influencer Pool: 2926. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, April 01, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Legionella Testing Industry” – https://www.reportlinker.com/p05961012/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. – Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: – Global Legionella Testing Market to Reach $421.9 Million by 2027 – Amid the COVID-19 crisis, the global market for Legionella Testing estimated at US$244.5 Million in the year 2020, is projected to reach a revised size of US$421.9 Million by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Culture Methods, one of the segments analyzed in the report, is projected to record a 8.4% CAGR and reach US$93 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Urinary Antigen Test (UAT) segment is readjusted to a revised 8.4% CAGR for the next 7-year period. – The U.S. Market is Estimated at $66.1 Million, While China is Forecast to Grow at 12.3% CAGR – The Legionella Testing market in the U.S. is estimated at US$66.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$95.7 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR. – Serology Segment to Record 7.1% CAGR – In the global Serology segment, USA, Canada, Japan, China and Europe will drive the 6.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.6 Million in the year 2020 will reach a projected size of US$22.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$58.6 Million by the year 2027, while Latin America will expand at a 8.4% CAGR through the analysis period. – Select Competitors (Total 41 Featured) – Alere, Inc.Aquacert LtdBeckman Coulter, Inc.Becton, Dickinson and Company (BD)BioMérieux SABio-Rad Laboratories, Inc.Eiken Chemical Co., Ltd.Hologic, Inc. Idexx Laboratories Inc.Roche DiagnosticsThermo Fischer Scientific, Inc. Read the full report: https://www.reportlinker.com/p05961012/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Legionella Testing by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Legionella Testing by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Legionella Testing by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Culture Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Culture Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Culture Methods by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Urinary Antigen Test (UAT) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Urinary Antigen Test (UAT) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Urinary Antigen Test (UAT) by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Serology by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Serology by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Serology by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Direct Fluorescence Antibody Test (DFA) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Direct Fluorescence Antibody Test (DFA) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Direct Fluorescence Antibody Test (DFA) by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Nucleic Acid-based Detection by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Nucleic Acid-based Detection by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Nucleic Acid-based Detection by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Clinical Testing Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Clinical Testing Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Clinical Testing Methods by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Environmental Testing Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Environmental Testing Methods by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Environmental Testing Methods by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Hospitals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 26: World Historic Review for Hospitals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 27: World 15-Year Perspective for Hospitals by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Diagnostic Laboratories by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 29: World Historic Review for Diagnostic Laboratories by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 30: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Clinics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 32: World Historic Review for Clinics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 33: World 15-Year Perspective for Clinics by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 34: World Current & Future Analysis for Other End-Uses by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 35: World Historic Review for Other End-Uses by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 36: World 15-Year Perspective for Other End-Uses by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 37: USA Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 38: USA Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 39: USA 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 40: USA Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 41: USA Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 42: USA 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 43: USA Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 44: USA Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 45: USA 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 CANADA Table 46: Canada Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 47: Canada Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 48: Canada 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 49: Canada Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: Canada Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 51: Canada 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 52: Canada Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 53: Canada Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 54: Canada 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 JAPAN Table 55: Japan Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 56: Japan Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 57: Japan 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 58: Japan Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 59: Japan Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 60: Japan 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 61: Japan Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 62: Japan Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 63: Japan 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 CHINA Table 64: China Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 65: China Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 66: China 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 67: China Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 68: China Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 69: China 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 70: China Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 71: China Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 72: China 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 EUROPE Table 73: Europe Current & Future Analysis for Legionella Testing by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 74: Europe Historic Review for Legionella Testing by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 75: Europe 15-Year Perspective for Legionella Testing by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 76: Europe Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 77: Europe Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 78: Europe 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 79: Europe Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 80: Europe Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 81: Europe 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 82: Europe Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 83: Europe Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 84: Europe 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 FRANCE Table 85: France Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 86: France Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 87: France 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 88: France Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 89: France Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 90: France 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 91: France Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 92: France Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 93: France 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 GERMANY Table 94: Germany Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 95: Germany Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 96: Germany 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 97: Germany Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 98: Germany Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 99: Germany 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 100: Germany Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 101: Germany Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 102: Germany 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 ITALY Table 103: Italy Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 104: Italy Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 105: Italy 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 106: Italy Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 107: Italy Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 108: Italy 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 109: Italy Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 110: Italy Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 111: Italy 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 112: UK Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 113: UK Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 114: UK 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection for the Years 2012, 2020 & 2027 Table 115: UK Current & Future Analysis for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 116: UK Historic Review for Legionella Testing by Application – Clinical Testing Methods and Environmental Testing Methods Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 117: UK 15-Year Perspective for Legionella Testing by Application – Percentage Breakdown of Value Sales for Clinical Testing Methods and Environmental Testing Methods for the Years 2012, 2020 & 2027 Table 118: UK Current & Future Analysis for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 119: UK Historic Review for Legionella Testing by End-Use – Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 120: UK 15-Year Perspective for Legionella Testing by End-Use – Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Clinics and Other End-Uses for the Years 2012, 2020 & 2027 SPAIN Table 121: Spain Current & Future Analysis for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 122: Spain Historic Review for Legionella Testing by Test Type – Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based Detection Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 123: Spain 15-Year Perspective for Legionella Testing by Test Type – Percentage Breakdown of Value Sales for Culture Methods, Urinary Antigen Test (UAT), Serology, Direct Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p05961012/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
